ESR2 and non-small cell lung carcinoma: In summary, the present study revealed that TFAP2A promotes NSCLC progression by mediating ESR2 and subsequently activating MAPK signalling pathways, and combined treatment with the ESR2 inhibitor TPHPP and targeted therapy synergistically inhibits tumour growth and improved patient prognosis.